Brief: Surrozen Anticipates Potential Proof-Of-Concept Data For Szn-1326 In Ulcerative Colitis In Second Half 2024

Surrozen

22/03/2023 20:06

March 22 (Reuters) - Surrozen Inc  SRZN.O :
    * SURROZEN PROVIDES FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL
RESULTS AND UPDATE ON CLINICAL PIPELINE AND CORPORATE PROGRESS
    * SURROZEN INC - CORPORATE PRIORITIZATION AND RESTRUCTURING
RESULT
IN CASH RUNWAY INTO SECOND HALF OF 2024
    * SURROZEN INC - ANTICIPATE POTENTIAL PROOF-OF-CONCEPT DATA
FOR
SZN-1326 IN ULCERATIVE COLITIS IN SECOND HALF OF 2024
    * SURROZEN INC - ENROLLED FIRST PATIENT IN SZN-043 PH 1A
CLINICAL
TRIAL IN CHRONIC LIVER DISEASE WITH DATA EXPECTED BY END OF 2023
    * SURROZEN- EXPECT TO BEGIN SZN-043 PH1B CLINICAL TRIAL IN
SEVERE
ALCOHOLIC HEPATITIS IN 2024 WITH PROOF-OF-CONCEPT DATA EXPECTED
IN SECOND HALF OF 2024
    * SURROZEN INC - EXPECT TO REINITIATE SZN-1326 PH1A CLINICAL
TRIAL
IN HEALTHY VOLUNTEERS BY MID-2023 WITH DATA EXPECTED BY END OF
2023
    * SURROZEN INC - : CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES WERE $75.8 MILLION AS OF DECEMBER 31, 2022

Source text for Eikon:  ID:nGNX6hVxzQ 
Further company coverage:  SRZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))